China gave the greenlight to Eli Lilly & Co.’s blockbuster drug tirzepatide for use in treating diabetes, a move that will ...
, opens new tab said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up ...
Eli Lilly and Company announced on Tuesday that the National Medical Products Administration (NMPA) in China has approved the ...
, opens new tab weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, lifting its shares nearly 5%. Lilly said it expects significant production ...
Eli Lilly & Co. said Wednesday that two late-stage trials evaluating a 10 mg or 15 mg injection of tirzepatide — the weight-loss drug marketed in the U.S. as Zepbound — reduced the severity of ...
14.05.24 S&P 500-Titel Eli Lilly and-Aktie: So viel Gewinn hätte eine Investition in Eli Lilly and von vor 5 Jahren abgeworfen 28.05.24 S&P 500-Papier Eli Lilly and-Aktie: So viel Gewinn hätte ...
Tuesday, Eli Lilly And Co (NYSE:LLY) reported first-quarter revenue of $8.77 billion, up 26% year over year, marginally missing ...
Angesichts der aktuellen Marktschwankungen warnen Experten vor überbewerteten Aktien - darunter namhafte S&P-500-Unternehmen.Die wichtigsten US-Indizes wie der S&P 500, der Nasdaq Composite und ...
We raise our Eli Lilly fair value estimate to $540 from $500 following stronger-than-expected first-quarter results. In particular, pricing drove 10 percentage points of the 26% top-line growth ...
Eli Lily’s weight-loss drug tirzepatide has been shown to “significantly” reduce sleep apnoea severity, the US drugs giant said on Wednesday. The firm said phase 3 clinical trials had showed ...
14.05.24 S&P 500-Titel Eli Lilly and-Aktie: So viel Gewinn hätte eine Investition in Eli Lilly and von vor 5 Jahren abgeworfen 28.05.24 S&P 500-Papier Eli Lilly and-Aktie: So viel Gewinn hätte ...